Gilteritinib is a clinically active FLT3 inhibitor with broad activity against FLT3 kinase domain mutations

Gilteritinib is the first FMS-like tyrosine kinase 3 (FLT3) tyrosine kinase inhibitor (TKI) approved as monotherapy in acute myeloid leukemia with FLT3 internal tandem duplication and D835/I836 tyrosine kinase domain (TKD) mutations. Sequencing studies in patients have uncovered less common, noncano...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Blood Adv
Hlavní autoři: Tarver, Theodore C., Hill, Jason E., Rahmat, Leena, Perl, Alexander E., Bahceci, Erkut, Mori, Kenichi, Smith, Catherine C.
Médium: Artigo
Jazyk:Inglês
Vydáno: American Society of Hematology 2020
Témata:
Myeloid Neoplasia
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC7013266/
https://ncbi.nlm.nih.gov/pubmed/32040554
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019000919
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky